Abstract
Despite the immense clinical success of the antibody therapeutics that neutralize programmed death receptor ligand 1 (PD-L1) and thus resurrect Tcell antitumor activity, the patient response rates remain low. In this issue of Cell Chemical Biology, Ludwig etal.1 reveal novel topologies of multiparatopic antibodies that mediate potent PD-L1 downregulation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have